Genmab — November 2019

Sukkeralf

Forstår dog godt at man vil have sc dosering i mål før man kaster sig over usikre studier i solide tumorer, hvor man i værste tilfald pludselig måske står med nogle dødsfald der kan kaste smuds over sc dara

E_L

agree. and JNJ clearly stated that they would wait with solid until the SC approval, that part is not new.

E_L

(why is Jan talking in the quiet period by the way??)

Sukkeralf

Probably just talking gibberish

E_L

thinking out-loud; given your concern on damaging the MM franchise with Dara solid trial; could they wait for HexaBody-CD38 and try it with that..?

Sukkeralf

Yes and no for you could end up the same way that deaths in a solid trial could jepardize the LCM in MM

Bulder

From the press announcement: "Next-generation HexaBody-CD38 could potentially add to the DARZALEX multiple myeloma franchise and expand the potential of CD38-targeted therapies in further indications" - could be solids

Helge_LarsenPI-redaktør

Kære venner. Jeg mangler i den grad spørgsmål til Q&A. Håber at de kommer hurtigst muligt.

Bulder

You had a Q at 10:41 E L

E_L

well ok then, i already asked when he expects to start the first trial, i'll also ask if he thinks it will make for a better option with solids

Sukkeralf

Vi skulle da også gerne snart se en IND/CTA for DuoHexa-CD37

E_L

maybe it is already in the report tomorrow, we have seen that before, they don't always do a separate press release

Sukkeralf

Agree - but that would be nice

Solsen

Vi skal nok levere spørgsmål Helge

Sukkeralf

Nogen forventninger til ASH abstracts i morgen:

Sukkeralf

https://www.hematology.org/Annual-Meeting/Abstracts/

bibob

Nok ikke så høje i år.

Helge_LarsenPI-redaktør

Tusinde tak Solsen. Jeg har Oncology i morgen, Genmab på Fredag og Zealand sener på måneden. Det trækker tænder ud i en allerede juletravl tid i produktion, grossist- og detailbranchen.

Relax

Hej Helge. Har lagt et spørgsmål til Genmabs kommende
Q&A på Genmab Q&A.

Solsen

Det første fra mig er sendt